Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Monday.

REGN has been the subject of several other reports. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a “buy” rating and a $890.00 price target for the company. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Sanford C. Bernstein increased their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $772.76.

Regeneron Pharmaceuticals Trading Down 0.2%

Shares of Regeneron Pharmaceuticals stock opened at $693.50 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The company has a market capitalization of $72.89 billion, a P/E ratio of 16.61, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $800.99. The company’s fifty day moving average is $598.76 and its two-hundred day moving average is $570.85.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the prior year, the firm earned $12.46 earnings per share. The business’s quarterly revenue was up .9% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Creative Planning grew its position in shares of Regeneron Pharmaceuticals by 110.2% in the third quarter. Creative Planning now owns 19,939 shares of the biopharmaceutical company’s stock valued at $11,211,000 after purchasing an additional 10,454 shares during the period. Lazard Asset Management LLC grew its holdings in Regeneron Pharmaceuticals by 4,035.5% in the 3rd quarter. Lazard Asset Management LLC now owns 10,380 shares of the biopharmaceutical company’s stock valued at $5,836,000 after buying an additional 10,129 shares during the period. SummitTX Capital L.P. acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $547,000. AQR Capital Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 528.7% during the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after acquiring an additional 606,612 shares during the period. Finally, Credit Agricole S A acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $19,367,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.